Top 10 Facts that Patients with Myeloproliferative Neoplasms Need to Know About Pacritinib (Vonjo)

Executive Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and MPN-focused Clinician Investigator, Ruben A. Mesa, MD, discusses the Top 10 Facts that Patients with Myeloproliferative Neoplasms (especially those with myelofibrosis) Need to Know About the FDA Approval of Pacritinib (Vonjo).

Follow Dr. Ruben Mesa on Twitter @mpdrc.
For more updates from the Mays Cancer Center, follow us on Facebook and Instagram @UTHealthSAMDAnderson and Twitter @UTHealthSAMDA.